全球领先的癌症组织负责人表示，香港正作为更广泛区域研究突破中心的重要组成部分发挥核心作用，并补充说，该市在降低吸烟率方面取得的成就为其他地区树立了榜样。
Hong Kong is playing a central role as part of a broader regional hub for research breakthroughs, the head of a leading global cancer organisation has said, adding that the city’s success in reducing its smoking rate has set an example for others to follow.
国际癌症控制联盟首席执行官凯里·亚当斯在该组织上月首次于香港举办世界癌症大会之际，对该市控烟工作予以了赞扬。
Cary Adams, CEO of the Union for International Cancer Control, praised the city’s tobacco control efforts as the organisation held the World Cancer Congress in Hong Kong last month for the first time.
“全球范围内，我们所有人都意识到，密集的研究和突破正来自世界这一地区，”亚当斯在9月底举行的世界癌症大会间隙接受《南华早报》采访时表示。
“We’ve all become aware globally that the centre of intense research and breakthrough is coming from this part of the world,” Adams told the South China Morning Post on the sidelines of the congress, which was held in late September.
“我们来到这里非常重要，因为这能让我们了解中国以及香港正在发生什么。”在回顾自己去年参加的一场癌症会议时，亚当斯描述了中国的科研活动增长情况。
“It was important for us to be here so we can understand what is happening in China, what is happening in Hong Kong.”Recalling his attendance at a cancer conference last year, Adams described the growth in research activity in China.
“看到中国正在开展的研究，以及从事这一领域的肿瘤科医生、研究人员和学者的数量，令人备受鼓舞，”他说。
“It’s inspirational to see the research that’s going on in China and the volume of oncologists and researchers, academics working in this space,” he said.
亚当斯表示，他相信中国在癌症的理解和治疗方面将取得更多突破，亚洲其他地区也将如此。
Adams said he was confident that further breakthroughs in understanding and treating cancer would come from China and elsewhere in Asia.
“我们希望置身于研究活动最集中的地方。这当然也是我们将这一重大癌症活动举办在香港的重要原因之一，”他在解释为何选择香港举办这一大型癌症活动时说道。
“We want to be in the centre of where the research is taking place. That’s certainly one of the big reasons that we came to this region,” he said, explaining why the major cancer event was held in Hong Kong.
亚当斯表示，其他地区希望从香港的控烟工作中汲取经验。正是这些努力，使香港的吸烟率从1982年的23.3%下降至去年的8.5%。
Adams said other places hoped to learn from the city’s tobacco control efforts, which had helped bring its smoking rate down from 23.3 per cent in 1982 to 8.5 per cent last year.
“这在世界上是前所未有的，”他说。“来到一个取得如此巨大成功的地区，我们组织中的许多人都会来到这里，他们想知道这一成果是如何实现的，政府采取了哪些措施。”
“This is unheard of around the world,” he said. “Coming to a place where they have been so incredibly successful, a lot of our community will come here, they want to know how that’s been achieved, what’s been done by the government.
“他们可以回到自己的国家，说：‘看，香港做到了，我们也能做到。’这正是我们所寻求的灵感来源。”吸烟是癌症的风险因素之一，也是香港大会讨论的主题之一。
“They can go back to their countries and say, look, Hong Kong did it, we could do it. So that’s the source of inspiration that we’re looking for.”Tobacco use is a risk factor for cancer and was among the themes discussed at the congress in Hong Kong.
世界卫生组织2024年发布的数据显示，全球吸烟率已逐步下降，从2000年的32.7%降至2025年估计的19.8%。但截至2024年，仍有40个国家尚未采取任何基于证据的控烟措施。
Data published by the World Health Organization in 2024 showed that the global prevalence of tobacco use had fallen gradually, from 32.7 per cent in 2000 to an estimated 19.8 per cent in 2025. But as of 2024, 40 countries had yet to adopt any evidence-based tobacco-control measures.
香港正努力成为国际健康与医疗创新枢纽，这一目标已写入该市的首个五年规划，并自2023年起被纳入政策讲话中。
Hong Kong is striving to become an international hub for health and medical innovation, an ambition outlined in the city’s first five-year plan and included in policy addresses since 2023.
亚当斯表示，此次大会汇集了来自124个国家的2000多名医疗代表，通过创造交流想法和建立合作的机会，将有助于香港实现这一目标。
Adams said the congress, which brought together more than 2,000 healthcare delegates from more than 124 countries, could help the city achieve that goal by creating opportunities for ideas and partnerships.
香港抗癌协会副主席安妮·李咏梅教授表示，香港可以在全球抗癌斗争中发挥更大的作用。她指出：“尽管香港规模不大，但我们的影响力不容小觑。”
Professor Anne Lee Wing-mui, vice-chairwoman of the Hong Kong Anti-Cancer Society, which organised the congress in the city, said Hong Kong could make a greater contribution to the global fight against cancer. “Even though Hong Kong is small, we’re not small in terms of impact,” she said.
作为香港顶尖的临床肿瘤学家，李咏梅表示，某些癌症，如肝癌和肺癌，在亚洲和西方患者中的特征存在差异。这为香港开展自主研究、补充现有知识提供了机会。
Lee, a leading clinical oncologist in Hong Kong, said some cancers, such as liver and lung cancer, had different characteristics in Asian and Western patients. That gave Hong Kong an opportunity to conduct its own research and supplement existing knowledge, she said.
她补充说，2021年至2025年间，共有1.2万篇与癌症相关的学术论文至少有一位来自香港的合著者，其中15%发表在顶级期刊上。
She added that between 2021 and 2025, there were 12,000 cancer-related academic papers which had at least one co-author from Hong Kong, and 15 per cent of them were published in top journals.
随着香港致力于扩大研究规模以成为创新枢纽，李咏梅表示，该市在按照国际标准开展研究方面，已经建立了良好的信誉和信任。
As Hong Kong sought to expand its research as part of its efforts to become an innovation hub, Lee said the city had already established credibility and trust in conducting studies to international standards.
“将部分研究从其他地方转移到世界这一地区会很有帮助，因为这里成本效益更高，”她说。
“It would be good to shift some of the research here to this part of the world because it’s much more cost-effective,” she said.
“在这里开展临床试验要便宜得多，而且你需要多样化且具有代表性的患者群体，才能真正获得高质量的数据。”随着香港与内地科研合作的不断加强，包括在边境附近设立河套深港科技创新合作区，李表示，香港可以利用粤港澳大湾区8600万人口的优势，开展临床试验和研究。
“It’s much less expensive to conduct a clinical trial, and you need a variety and diversity of patient population to really come up with good data.”As Hong Kong strengthens its research ties with the mainland, including through the establishment of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone near the border, Lee said the city could draw on the Greater Bay Area’s population of 86 million for trials and studies.
粤港澳大湾区是一项发展规划，旨在将香港、澳门以及广东省内的另外九个城市打造成一个高科技经济与商业中心。亚当斯表示，与内地的合作可能使香港在癌症研究方面占据优势。
The bay area is a development blueprint that aims to turn Hong Kong, Macau and nine other cities in Guangdong province into a hi-tech economic and business powerhouse. Adams said collaboration with the mainland could give Hong Kong an edge in cancer research.
“肿瘤科医生的数量、研究人员的人数以及患者的数量——这些数字都极为惊人，”他说。“在癌症治疗与护理的研究领域，这正是关键性的竞争优势。”
“The number of oncologists, the number of researchers, the number of patients. The numbers are extraordinary,” he said. “That is a key competitive advantage when it comes to research in cancer treatment and care.”